The Food and Drug Administration has given its long-awaited approval for Novavax’s COVID-19 vaccine, but with some unusual restrictions. Novavax is known for producing the nation’s only traditional protein-based coronavirus vaccine, which previously had emergency authorization for use in individuals aged 12 and older.
However, the FDA’s full approval for Novavax’s vaccine is now limited to adults aged 65 and older, or individuals aged 12 to 64 with underlying health conditions that increase their risk from COVID-19. This decision contrasts with the full licensure of Pfizer and Moderna’s vaccines, which are approved for use in individuals as young as 12 years old.
Novavax CEO John C. Jacobs expressed his satisfaction with the licensure, stating that the company’s market research and CDC statistics suggest that older individuals and those with underlying conditions are most likely to seek out COVID-19 vaccination seasonally.
The FDA’s decision to impose restrictions on Novavax’s vaccine approval may be influenced by skepticism about vaccines from Health Secretary Robert F. Kennedy Jr. and other Trump administration officials. Despite showing safety and efficacy in a 30,000-person clinical trial, Novavax will be required to conduct additional trials, including some investigating potential associations with heart conditions.
Overall, the FDA’s approval process for Novavax’s COVID-19 vaccine has raised questions and may impact future decisions on vaccine recommendations. It remains to be seen how this development will shape the landscape of COVID-19 vaccination moving forward.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
